TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results
TYME Technologies announced significant advancements, including the first patient dosed in the Phase II OASIS trial for metastatic breast cancer, and plans to expand clinical trial sites for the PanCAN Precision Promise trial. The company reported a robust cash position of $96.6 million as of September 30, 2021, and a reduced operational cash burn rate of $5.0 million for Q2 FY 2022. With a net loss of $5.6 million or $0.03 per share, improvements in financial metrics were noted compared to the prior year, bolstering confidence in ongoing clinical efforts.
- First patient enrolled in the Phase II OASIS trial for breast cancer.
- Cash position of $96.6 million as of September 30, 2021.
- Reduced operational cash burn rate to $5.0 million in Q2 FY 2022.
- Net loss of $5.6 million for Q2 FY 2022, despite improvements.
– First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor –
– PanCAN Precision Promise trial to add five new sites in early 2022 –
– Commenced preclinical initiative with Evotec, a global leader in drug development, to evaluate the potential of expanding our SM-88 platform to other indications –
– Maintained a well-capitalized position, with
– Company to host live conference call and webcast today,
Second Fiscal Quarter 2022 Business and Recent Highlights:
-
Commenced enrollment and dosed first patient in OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study examining SM-88 with methoxsalen, phenytoin, and sirolimus (MPS) in patients with metastatic disease who have received two prior hormonal therapies. The trial is being conducted by
Georgetown University (NCT04720664) at fiveMedStar Health hospitals. (MedStar Health is Georgetown’s academic clinical partner). -
Five new sites planned to be added in early 2022 with an additional 10 sites expected by the end of 2022, on top of the 15 already participating (for a total of 30 sites), in the Precision Promise trial, a Phase II/III randomized adaptive trial in metastatic pancreatic cancer sponsored by the
Pancreatic Cancer Action Network (PanCAN). These sites are among the top research institutions in the country for pancreatic cancer treatment. - The HOPES Sarcoma trial, an investigator-sponsored trial, had a meaningful increase in the rate of enrollment during the quarter. We anticipate completing trial enrollment by the end of the first half of calendar year 2022.
- Launched preclinical initiative with Evotec to evaluate the potential of expanding SM-88 platform to other targeted indications.
- Announced plans to explore the development of a Tyrosine-based tumor targeted technology and the receipt of a patent on such platform.
“Our second quarter was a period of significant action at TYME as we continued to implement our strategic imperatives. We commenced the OASIS breast cancer study with the first patient dosed in late September, and initiated our preclinical work, including our all-important biomarker research. We believe this will provide us with a better understanding of how best to address treatment opportunities. Our existing trials are also progressing, as planned. PanCAN’s Precision Promise trial is in the process of seeking five new sites early next year with plans to add 10 more by the end of the year and enrollment continues in our HopES sarcomas study. This is particularly noteworthy given how difficult it is to recruit patients with this ultra-rare sarcoma. Finally, we began early discovery work on a tyrosine-based tumor targeted technology platform,” stated
“Given all the positive momentum, these are exciting times at TYME, and we are in a strong financial position to advance these programs. We look forward to sharing information on our progress in the upcoming quarters,” concluded Cunningham.
Second Fiscal Quarter 2022 Financial Results
As of the quarter ended
The burn rate was below the Company’s previous guidance and reflected expenses associated with ongoing clinical trials in pancreatic cancer (Precision Promise), breast cancer (Oasis), and sarcoma cancers (HopES), as well as reduced costs associated with our discontinued pancreatic cancer trial, 88-Panc-Part II. TYME continues to anticipate that its quarterly cash usage or “cash burn rate” will range from
Net loss was
After adjusting for the change in fair value of warrant liability, and amortization of employee, director and consultant stock options, adjusted net loss for the three months ended
TYME has reported its full financial results for the quarter ended
Conference Call and Webcast Details
| Date: | ||||
| Time: | ||||
| Toll-free ( |
(866) 601-3896 | |||
| International | (636) 812-6499 | |||
| Conference ID | 5953454 |
The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com, and will be archived for 90 days following the event.
Use of Non-GAAP Measures
Adjusted net loss and adjusted net loss per share as presented in this report are non-GAAP measures. The adjustments relate to the change in fair value of warrant liability, amortization of employees, directors and consultants stock options and gain on warrant exchange. These financial measures are presented on a basis other than in accordance with
About
TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to cause cancer cell death.
The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, reinforce the potential of its emerging CMBT™ pipeline.
For more information about the Company, visit www.tymeinc.com and connect on Facebook, LinkedIn, and Twitter.
About SM-88
SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. SM-88 is being evaluated in an adaptive randomized Phase 2/3 clinical trial for patients with second-line pancreatic cancer. The Company has begun enrollment in a Phase II study evaluating SM-88 in breast cancer (HR+/HER2-) in the third quarter of calendar year 2021, as well as continuing enrollment of a Phase II study in high-risk metastatic sarcomas. SM-88 is an investigational therapy that is not approved for any indication in any disease.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates (including SM-88 and TYME- 18) and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical or clinical trials, , preliminary data results and the therapeutic design and mechanisms of our drug candidates. The words “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” “anticipates,” and similar expressions (including their use in the negative) are intended to identify forward-looking statements. Forward-looking statements can also be identified by discussions of future matters such as: the effect of the COVID-19 pandemic and the associated impact on the national and global economy as well as impacts on the Company's ongoing clinical trials and ability to analyze data from those trials; the cost of development and potential commercialization of our lead drug candidate and of other new product candidates; expected releases of interim or final data from our clinical trials; possible collaborations; the timing, scope, status, objectives of our ongoing and planned trials; the success of management transitions and strategic initiatives; and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations and projections which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include but are not limited to: the severity, duration, and economic impact of the COVID-19 pandemic; our ability to achieve the intended benefits of our strategic initiatives; that certain information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply, and in the ability to achieve adequate start and completion dates, as well as uncertainties in clinical trial design and patient enrollment, dropout or discontinuation rates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trials may differ from prior or preliminary study data or analyses and may not support further clinical development; and that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 or other drug candidates may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88 or other drug candidates; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K for the fiscal year ended
The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.
Financial Tables Follow
| Condensed Consolidated Statement of Operations and Comprehensive Loss | |||||||||||
| (Unaudited) | |||||||||||
| Three Months Ended |
Six Months Ended |
||||||||||
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| Revenues | $ |
— |
$ |
— |
$ |
— |
$ |
— |
|||
| Operating expenses: | |||||||||||
| Research and development |
|
3,495,416 |
|
4,707,448 |
|
7,679,827 |
|
9,422,743 |
|||
| General and administrative (including |
|
2,433,099 |
|
2,613,689 |
|
4,901,258 |
|
5,670,761 |
|||
| Total operating expenses |
|
5,928,515 |
|
7,321,137 |
|
12,581,085 |
|
15,093,504 |
|||
| Loss from operations |
|
(5,928,515) |
|
(7,321,137) |
|
(12,581,085) |
|
(15,093,504) |
|||
| Other income (expense): | |||||||||||
| Change in fair value of warrant liability |
|
344,166 |
|
489,572 |
|
1,069,309 |
|
(2,773,699) |
|||
| Gain on warrant exchange |
|
— |
|
— |
|
— |
|
2,228,697 |
|||
| Other income |
|
39,007 |
|
7,011 |
|
58,530 |
|
17,513 |
|||
| Interest expense |
|
(19,368) |
|
(25,980) |
|
(40,627) |
|
(55,356) |
|||
| Total other income (expense) |
|
363,805 |
|
470,603 |
|
1,087,212 |
|
(582,845) |
|||
| Net loss | $ |
(5,564,710) |
$ |
(6,850,534) |
$ |
(11,493,873) |
$ |
(15,676,349) |
|||
| Basic and diluted loss per common share | $ |
(0.03) |
$ |
(0.05) |
$ |
(0.07) |
$ |
(0.12) |
|||
| Basic and diluted weighted average shares outstanding |
|
172,206,894 |
|
128,046,895 |
|
172,206,177 |
|
126,323,921 |
|||
| Statements of Comprehensive Loss | |||||||||||
| Net loss | $ |
(5,564,710) |
$ |
(6,850,534) |
$ |
(11,493,873) |
$ |
(15,676,349) |
|||
| Other comprehensive loss | |||||||||||
| Unrealized loss on marketable securities, net of tax |
|
(24,715) |
|
- |
|
(58,557) |
|
- |
|||
| Comprehensive loss | $ |
(5,589,425) |
$ |
(6,850,534) |
$ |
(11,552,430) |
$ |
(15,676,349) |
|||
| Reconciliation of Net Loss to Adjusted Net Loss | ||||||||||||
| Three Months Ended |
Six Months Ended |
|||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
|||||
| Net loss (GAAP) | $ |
(5,565,000) |
$ |
(6,851,000) |
$ |
(11,494,000) |
$ |
(15,676,000) |
||||
| Adjustments: | ||||||||||||
| Change in fair value of warrant liability |
|
(344,000) |
|
(490,000) |
|
(1,069,000) |
|
2,774,000 |
||||
| Amortization of employees, directors and consultants stock options |
|
616,000 |
|
884,000 |
|
1,260,000 |
|
1,953,000 |
||||
| Gain on warrant exchange |
|
— |
|
— |
|
— |
|
(2,229,000) |
||||
| Adjusted net loss (non-GAAP) | $ |
(5,293,000) |
$ |
(6,457,000) |
$ |
(11,303,000) |
$ |
(13,178,000) |
||||
| Reconciliation of Net Loss Per Share to Adjusted Net Loss Per Share | ||||||||||||
| Three Months Ended |
Six Months Ended |
|||||||||||
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
||
| Net loss per share (GAAP) | $ |
(0.03) |
$ |
(0.05) |
$ |
(0.07) |
$ |
(0.12) |
||||
| Adjustments: | ||||||||||||
| Change in fair value of warrant liability | * | * |
|
(0.01) |
|
0.02 |
||||||
| Amortization of employees, directors and consultants stock options | * |
|
0.01 |
|
0.01 |
|
0.02 |
|||||
| Gain on warrant exchange |
|
— |
|
— |
|
— |
|
(0.02) |
||||
| Adjusted net loss per share (non-GAAP) | $ |
(0.03) |
$ |
(0.04) |
$ |
(0.07) |
$ |
(0.10) |
||||
| * The effect of the change was negligible to the adjusted net loss per share. | ||||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005305/en/
Investor Relations:
T: 212-452-2793
E: lwilson@insitecony.com
Source:
FAQ
What is the status of TYME's Phase II OASIS trial for breast cancer?
How much cash does TYME Technologies have as of September 30, 2021?
What was TYME's operational cash burn rate in Q2 FY 2022?
What was TYME's net loss for the quarter ended September 30, 2021?
What are the future plans for TYME's clinical trials?
